Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 18/20 | 0.55 |
| ▸ | CYSLTR2 | Q9NS75 | 17/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622008 | 1.00 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2FFAR1PPARGPPARD | |
| SCHEMBL3622003 | 1.00 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2FFAR1PPARGPPARD | |
| SCHEMBL3565176 | 0.93 | CYSLTR2 (0.54) | CYSLTR1CYSLTR2 | |
| SCHEMBL3565175 | 0.93 | CYSLTR2 (0.54) | CYSLTR1CYSLTR2 | |
| SCHEMBL3565172 | 0.93 | CYSLTR2 (0.54) | CYSLTR1CYSLTR2 | |
| SCHEMBL3558208 | 0.93 | CYSLTR2 (0.60) | CYSLTR1CYSLTR2PPARALTB4RLTB4R2 | |
| SCHEMBL3558212 | 0.93 | CYSLTR2 (0.60) | CYSLTR1CYSLTR2PPARALTB4RLTB4R2 | |
| SCHEMBL3558203 | 0.93 | CYSLTR2 (0.60) | CYSLTR1CYSLTR2PPARALTB4RLTB4R2 | |
| SCHEMBL3626741 | 0.92 | CYSLTR2 (0.58) | CYSLTR1CYSLTR2PPARALTB4RLTB4R2 | |
| SCHEMBL3626739 | 0.92 | CYSLTR2 (0.58) | CYSLTR1CYSLTR2PPARALTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188532-A1 | Indole Compound and Use Thereof | CYSLTR1, LTC4S, IDO1 | CYSLTR1 1/4885CYSLTR2 4/4885FFAR1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.